drugset / Trial / NCT06881251
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Timeline
- Start
- 2025-02-26
- Primary completion
- 2026-03-26
- Completion
- 2026-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | — | Subcutaneous |
| Subject | JNJ-95475939 | Unknown | — | Subcutaneous |